SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that data demonstrating the power of its DNA sequencing-based LymphoSIGHTTM platform for the detection of Minimal Residual Disease (MRD) was presented during the European Hematology Association (EHA) meeting in Amsterdam June 15.
